This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

Motus GI Holdings Dirección

Dirección controles de criterios 3/4

El CEO de Motus GI Holdings es Mark Pomeranz , nombrado en Apr 2023, tiene una permanencia de menos de un año. compensación anual total es $515.51K, compuesta por 74.7% salario y 25.3% primas, incluidas acciones y opciones de la empresa. posee directamente un 0.01% de las acciones de la empresa, por valor de €134.88. La antigüedad media del equipo directivo y de la junta directiva es de 0.6 años y 5.5 años, respectivamente.

Información clave

Mark Pomeranz

Chief Executive Officer (CEO)

US$515.5k

Compensación total

Porcentaje del salario del CEO	74.7%
Permanencia del CEO	less than a year
Participación del CEO	0.009%
Permanencia media de la dirección	less than a year
Promedio de permanencia en la Junta Directiva	5.5yrs

Actualizaciones recientes de la dirección

Recent updates

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de Mark Pomeranz en comparación con los beneficios de Motus GI Holdings?
Fecha	Compensación total	Salario	Ingresos de la empresa
Sep 30 2023	n/a	n/a	-US$14m
Jun 30 2023	n/a	n/a	-US$16m
Mar 31 2023	n/a	n/a	-US$18m
Dec 31 2022	US$516k	US$385k	-US$19m
Sep 30 2022	n/a	n/a	-US$20m
Jun 30 2022	n/a	n/a	-US$20m
Mar 31 2022	n/a	n/a	-US$19m
Dec 31 2021	US$858k	US$385k	-US$25m
Sep 30 2021	n/a	n/a	-US$25m
Jun 30 2021	n/a	n/a	-US$24m
Mar 31 2021	n/a	n/a	-US$24m
Dec 31 2020	US$825k	US$385k	-US$19m
Sep 30 2020	n/a	n/a	-US$21m
Jun 30 2020	n/a	n/a	-US$22m
Mar 31 2020	n/a	n/a	-US$23m
Dec 31 2019	US$1m	US$385k	-US$23m
Sep 30 2019	n/a	n/a	-US$23m
Jun 30 2019	n/a	n/a	-US$23m
Mar 31 2019	n/a	n/a	-US$21m
Dec 31 2018	US$502k	US$359k	-US$22m
Sep 30 2018	n/a	n/a	-US$20m
Jun 30 2018	n/a	n/a	-US$18m
Mar 31 2018	n/a	n/a	-US$18m
Dec 31 2017	US$2m	US$350k	-US$13m

Compensación vs. Mercado: La compensación total ($USD515.51K) de Mark está en línea con el promedio de empresas de tamaño similar en el mercado German ($USD486.57K).

Compensación vs. Ingresos: La compensación de Mark ha sido consistente con los resultados de la empresa en el último año.

CEO

Mark Pomeranz (61 yo)

less than a year

Permanencia

US$515,505

Compensación

Mr. Mark Pomeranz serves as Chief Executive Officer of Motus GI Holdings, Inc. since April 13, 2023. He had been President and Chief Operating Officer of Motus GI Holdings Inc. since September 24, 2018 unt...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Mark Pomeranz	Non-Independent Director & CEO	less than a year	US$515.51k	0.0095% € 134.9
Ravit Ram	CFO & VP of Global Operations	less than a year	sin datos	0% € 0
Elad Amor	Chief Accounting Officer	less than a year	sin datos	0% € 0

0.6yrs

Permanencia media

Equipo directivo experimentado: El equipo directivo de 7M4 no se considera experimentado ( 0.6 años antigüedad media), lo que sugiere un nuevo equipo.

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Mark Pomeranz	Non-Independent Director & CEO	8yrs	US$515.51k	0.0095% € 134.9
Steven Edmundowicz	Member of Medical Advisory Board	no data	sin datos	sin datos
David Lieberman	Member of Medical Advisory Board	no data	sin datos	sin datos
Gary John Pruden	Independent Director	6.1yrs	US$73.84k	0.048% € 676.4
Scott Durbin	Director	less than a year	sin datos	sin datos
Seth Gross	Member of Advisory Board	5.7yrs	sin datos	sin datos
Sonja Nelson	Independent Director	2.6yrs	US$62.29k	0.022% € 307.4
Ian Gralnek	Member of Medical Advisory Board	no data	sin datos	sin datos
Brian Jacobson	Member of Medical Advisory Board	no data	sin datos	sin datos
Peter Siersema	Member of Medical Advisory Board	no data	sin datos	sin datos
Gerald Bertiger	Member of Medical Advisory Board	no data	sin datos	sin datos
Timothy Moran	Independent Chairman	5.3yrs	US$683.60k	0.032% € 453.3

5.5yrs

Permanencia media

54yo

Promedio de edad

Junta con experiencia: La junta directiva de 7M4 se considera experimentada (5.5 años de antigüedad promedio).

This company listing is no longer active

Motus GI Holdings Dirección

Dirección controles de criterios 3/4

Información clave

Actualizaciones recientes de la dirección

Motus GI Holdings, Inc. Announces Executive Changes

Motus GI Holdings, Inc., Annual General Meeting, Sep 21, 2023

Shervin Korangy Resigns from the Board of Directors of Motus GI Holdings, Inc

Motus GI Holdings, Inc. Announces Executive Changes

Insufficient new directors

Motus GI Holdings, Inc., Annual General Meeting, Jun 30, 2022

Recent updates

Motus GI Holdings, Inc.(OTCPK:MOTS) dropped from S&P TMI Index

Motus GI Holdings, Inc.(OTCPK:MOTS) dropped from NASDAQ Composite Index

Motus GI Holdings Receive Non-Compliance Letter from Nasdaq Related to Listing Rule 5550(a)(2)

Motus GI Holdings, Inc. Publishes Positive Results from A European Study of the Second Generation Pure-Vu System in Improving Visualization for Colonoscopy in Patients with A History of Poor Bowel Preparation

Motus GI Holdings, Inc. Announces First Upper GI Patient Procedure for FDA Cleared Pure-Vu®? EVS Gastro

Motus GI Holdings, Inc. Receives Fda Clearance to Commercialize Pure-Vu Evs Gastro and Gen 4 Colon

Motus GI Holdings Announces Update on Non-Compliance with Minimum Bid Price Requirement for Continued Listing on the Nasdaq Capital Market

Motus GI Holdings, Inc. Announces Executive Changes

New major risk - Financial position

Second quarter 2023 earnings released: US$0.40 loss per share (vs US$1.86 loss in 2Q 2022)

Motus GI Holdings, Inc. Receives Approval from the Israeli Ministry of Health to Initiate Commercial Sales of Its Pure-Vu® EVS System

Motus GI Holdings, Inc., Annual General Meeting, Sep 21, 2023

Shervin Korangy Resigns from the Board of Directors of Motus GI Holdings, Inc

Motus GI Holdings Provides Shareholder's Equity Compliance Update

Motus GI Announces Pure-Vu Gen 4 Gastro and Colon System Featured at 9th IECED Live Endoscopy Course 2023 At the Pentax Learning Center

Motus GI Holdings, Inc. Announces Executive Changes

Motus GI Holdings, Inc. announced that it expects to receive $3.5 million in funding

Motus GI Holdings, Inc. Completes First Clinical Evaluation of New Pure-Vu(R) Gastro in Upper Gastrointestinal Procedures to Support Fda Submission

First quarter 2023 earnings released: US$0.92 loss per share (vs US$1.86 loss in 1Q 2022)

Motus GI Holdings Receives Non-Compliance Notice From Nasdaq

Motus GI Holdings, Inc. Announces Improvement of Pure-Vu® EVS System for Use in Upper Gastrointestinal (GI) Bleeding Procedures Following Successful Pre-Clinical Tests

Insufficient new directors

Motus GI Holdings, Inc. to Report Q3, 2022 Results on Nov 14, 2022

Second quarter 2022 earnings released: US$1.86 loss per share (vs US$1.99 loss in 2Q 2021)

Motus GI Regains Compliance with Nasdaq Minimum Bid Price Requirement

Motus GI Holdings, Inc. to Report Q2, 2022 Results on Aug 11, 2022

Motus GI Holdings Announces Positive Topline Data from EU Study of the Pure-Vu System in Hard-to-Prepare Patients Presented at Digestive Disease Week 2022

Motus GI Holdings Announces Positive Topline Data from EU Study of the Pure-Vu System in Hard-to-Prepare Patients Presented at Digestive Disease Week 2022

Motus GI Holdings, Inc., Annual General Meeting, Jun 30, 2022

First quarter 2022 earnings released: US$0.093 loss per share (vs US$0.26 loss in 1Q 2021)

Insufficient new directors

Motus GI Completes Enrollment in the European Union Feasibility Study of the Pure-Vu System as a New Method for Bowel Cleansing in Patients with a History of Poor Bowel Preparation

Full year 2021 earnings released: US$0.54 loss per share (vs US$0.60 loss in FY 2020)

Motus GI Grants 180-Day Extension to Meet NASDAQ Minimum Bid Price Requirement

Motus GI Holdings, Inc. Receives FDA Clearance to Market the Pure-Vu® EVS System

Third quarter 2021 earnings released: US$0.10 loss per share (vs US$0.13 loss in 3Q 2020)

Insufficient new directors

Independent Director Samuel Nussbaum has left the company

Second quarter 2021 earnings released: US$0.099 loss per share (vs US$0.15 loss in 2Q 2020)

Motus GI Announces First Patients Enrolled in the European Union Feasibility Study of the Pure-Vu® System as a New Method for Bowel Cleansing in Patients With a History of Poor Bowel Preparation

First quarter 2021 earnings released: US$0.26 loss per share (vs US$0.23 loss in 1Q 2020)

Forecast to breakeven in 2025

Motus Gi Holdings, Inc. Announces Publication of A Pure-Vu System® Cost Effectiveness Analysis in the Journal of Cost Effectiveness and Resource

Motus GI Receives FDA Clearance to Market the Pure-Vu® System for Upper GI Endoscopy

Análisis de compensación del CEO

CEO

Permanencia

Compensación

Equipo directivo

Permanencia media

Miembros de la Junta

Permanencia media

Promedio de edad